 |
|
Designing Appropriate Therapy in the Treatment of Gram-Negative Bacillary Meningitis
Michael L. Corrado, MD;
Myles E. Gombert, MD;
Charles E. Cherubin, MD
JAMA. 1982;248(1):71-74.
Abstract
Gram-negative bacillary meningitis is being diagnosed more frequently, and the introduction of newer β-lactam antibiotics has contributed significantly to successful therapy. These new agents—because of their ease of administration and relative safety—also allow nonspecialists to treat the disease. There are, however, pitfalls in therapy of infections due to this heterogenous group of organisms. Extremely susceptible organisms, such as Escherichia coli and Klebsiella pneumoniae, most often respond to cephalosporin monotherapy, whereas relatively resistant organisms such as Acinetobacter and some Enterobacter may not. In these cases, combination therapy with an aminoglycoside is warranted. Testing the infecting organism for antibiotic susceptibility at the appropriate inoculum and pH may be useful in predicting therapeutic outcome.
(JAMA 1982;248:71-74)
Author Affiliations
From the State University of New York Downstate Medical Center, Brooklyn (Drs Corrado and Gombert), and the Jewish Hospital and Medical Center of Brooklyn, Brooklyn, NY (Dr Cherubin).
Footnotes
Reprint requests to The Jewish Hospital and Medical Center of Brooklyn, 555 Prospect PI, Brooklyn, NY 11239 (Dr Cherubin).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Trimethoprim-Sulfamethoxazole for Bacterial Meningitis
LEVITZ and QUINTILIANI
ANN INTERN MED 1984;100:881-890.
ABSTRACT
Cefotaxime Therapy: Evaluation of Its Effect on Bacterial Meningitis, CSF Drug Levels, and Bactericidal Activity
Mullaney and John
Arch Intern Med 1983;143:1705-1708.
ABSTRACT
|
